Asher Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Asher Biotherapeutics's estimated annual revenue is currently $5.4M per year.
- Asher Biotherapeutics's estimated revenue per employee is $180,833
- Asher Biotherapeutics's total funding is $163.2M.
Employee Data
- Asher Biotherapeutics has 30 Employees.
- Asher Biotherapeutics grew their employee count by -6% last year.
Asher Biotherapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder, CSO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP, Regulatory Affairs | Reveal Email/Phone |
4 | VP Translational Research and Medicine | Reveal Email/Phone |
5 | VP Finance | Reveal Email/Phone |
6 | VP, Business and Commercial Strategy | Reveal Email/Phone |
7 | VP and Head CMC | Reveal Email/Phone |
8 | Director, Drug Substance Process Development | Reveal Email/Phone |
9 | Associate Director, Immune Targeting | Reveal Email/Phone |
10 | Chief Technology Officer, Founder | Reveal Email/Phone |
Asher Biotherapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Asher Biotherapeutics?
We build immunotherapies.
keywords:N/A$163.2M
Total Funding
30
Number of Employees
$5.4M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Asher Biotherapeutics News
--(BUSINESS WIRE)--Asher Biotherapeutics (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer,...
Lonza and Asher Biotherapeutics have entered a manufacturing agreement for a cis-targeted IL-2 fusion protein, AB359.
Asher Biotherapeutics, which is developing targeted immunotherapies for cancer, autoimmune, and infectious diseases, and Lonza, a CDMO,...
Asher Biotherapeutics, a South San Francisco CA-based biotechnology company, raised $108M in Series B funding. The round was led by Wellington Management Company LLP with participation from RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace, Alexandria Venture Invest ...
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of an oversubscribed Series B financing, which raised $108 million. The financing was led by Wellington Management Company LLP ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.4M | 30 | -12% | N/A |
#2 | $5M | 30 | 11% | N/A |
#3 | $7.5M | 31 | -6% | $7.4M |
#4 | $10.7M | 31 | 3% | N/A |
#5 | $7.1M | 32 | 14% | N/A |